 Affimed NV NASDAQ: AFMD has announced the publication of in vitro and in vivo research of its lead innate cell engager ICE, AFM13 CD16ACD30, combined with healthy donor-derived Natural killer NK cells, in Clinical Cancer Research. The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK cbNK cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity. 